• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Potential of recombinant opa proteins as vaccine candidates against hyperinvasive meningococci.重组 Opa 蛋白作为针对高侵袭性脑膜炎奈瑟菌疫苗候选物的潜力。
Infect Immun. 2011 Jul;79(7):2810-8. doi: 10.1128/IAI.01338-10. Epub 2011 Apr 4.
2
Construction of Opa-positive and Opa-negative strains of Neisseria meningitidis to evaluate a novel meningococcal vaccine.构建 Opa 阳性和 Opa 阴性脑膜炎奈瑟菌菌株,以评估一种新型脑膜炎球菌疫苗。
PLoS One. 2012;7(12):e51045. doi: 10.1371/journal.pone.0051045. Epub 2012 Dec 12.
3
Opacity-associated adhesin repertoire in hyperinvasive Neisseria meningitidis.高侵袭性脑膜炎奈瑟菌中与不透明度相关的黏附素库
Infect Immun. 2006 Sep;74(9):5085-94. doi: 10.1128/IAI.00293-06.
4
Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins.用含有重组脑膜炎球菌OpaB和OpaJ蛋白的脂质体对小鼠进行鼻内免疫。
Vaccine. 2004 Sep 28;22(29-30):4021-8. doi: 10.1016/j.vaccine.2004.03.047.
5
Expression of human CEACAM1 in transgenic mice limits the Opa-specific immune response against meningococcal outer membrane vesicles.人细胞上皮黏附分子 1 在转基因小鼠中的表达限制了对脑膜炎奈瑟菌外膜囊泡的 Opa 特异性免疫应答。
Vaccine. 2013 Nov 12;31(47):5585-93. doi: 10.1016/j.vaccine.2013.07.069. Epub 2013 Aug 6.
6
Bactericidal Antibody Responses to Meningococcal Recombinant Outer Membrane Proteins.针对脑膜炎球菌重组外膜蛋白的杀菌抗体反应。
J Microbiol Biotechnol. 2024 Jul 28;34(7):1419-1424. doi: 10.4014/jmb.2401.01018. Epub 2024 Apr 24.
7
Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.抗A群脑膜炎奈瑟菌外膜囊泡疫苗的研发与特性分析
Vaccine. 2005 May 31;23(29):3762-74. doi: 10.1016/j.vaccine.2005.02.021. Epub 2005 Mar 14.
8
Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.基于乳酸奈瑟菌外膜囊泡的候选脑膜炎球菌病疫苗的I期安全性和免疫原性研究。
Clin Vaccine Immunol. 2009 Aug;16(8):1113-20. doi: 10.1128/CVI.00118-09. Epub 2009 Jun 24.
9
Functional activity of antibodies against the recombinant OpaJ protein from Neisseria meningitidis.针对脑膜炎奈瑟菌重组OpaJ蛋白的抗体的功能活性
Infect Immun. 2003 May;71(5):2331-40. doi: 10.1128/IAI.71.5.2331-2340.2003.
10
The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate.脑膜炎奈瑟菌巨噬细胞感染增强蛋白诱导交叉株血清杀菌活性,是一种有潜力的 B 群疫苗候选物。
Infect Immun. 2011 Sep;79(9):3784-91. doi: 10.1128/IAI.05019-11. Epub 2011 Jun 27.

引用本文的文献

1
Bactericidal Antibody Responses to Meningococcal Recombinant Outer Membrane Proteins.针对脑膜炎球菌重组外膜蛋白的杀菌抗体反应。
J Microbiol Biotechnol. 2024 Jul 28;34(7):1419-1424. doi: 10.4014/jmb.2401.01018. Epub 2024 Apr 24.
2
vaccines: a contemporary overview.疫苗:当代概述。
Clin Microbiol Rev. 2024 Mar 14;37(1):e0009423. doi: 10.1128/cmr.00094-23. Epub 2024 Jan 16.
3
Progress Toward a Gonococcal Vaccine: The Way Forward.迈向淋球菌疫苗的进展:前进之路。
Front Immunol. 2019 Oct 15;10:2417. doi: 10.3389/fimmu.2019.02417. eCollection 2019.
4
Targeting Lipooligosaccharide (LOS) for a Gonococcal Vaccine.针对淋病奈瑟菌脂寡糖(LOS)的疫苗目标。
Front Immunol. 2019 Feb 27;10:321. doi: 10.3389/fimmu.2019.00321. eCollection 2019.
5
Quantitative Proteomics of the 2016 WHO Reference Strains Surveys Vaccine Candidates and Antimicrobial Resistance Determinants.2016 年世卫组织参考菌株调查疫苗候选物和抗微生物药物耐药性决定因素的定量蛋白质组学研究。
Mol Cell Proteomics. 2019 Jan;18(1):127-150. doi: 10.1074/mcp.RA118.001125. Epub 2018 Oct 23.
6
Characterisation of the Immunomodulatory Effects of Meningococcal Opa Proteins on Human Peripheral Blood Mononuclear Cells and CD4+ T Cells.脑膜炎球菌Opa蛋白对人外周血单个核细胞和CD4 + T细胞免疫调节作用的表征
PLoS One. 2016 Apr 25;11(4):e0154153. doi: 10.1371/journal.pone.0154153. eCollection 2016.
7
Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development.淋球菌病可以预防吗?了解免疫和发病机制在疫苗研发中的重要性。
Crit Rev Microbiol. 2016 Nov;42(6):928-41. doi: 10.3109/1040841X.2015.1105782. Epub 2016 Jan 23.
8
Adjuvant effects elicited by novel oligosaccharide variants of detoxified meningococcal lipopolysaccharides on Neisseria meningitidis recombinant PorA protein: a comparison in mice.解毒的脑膜炎奈瑟菌脂多糖新型寡糖变体对脑膜炎奈瑟菌重组PorA蛋白的佐剂效应:小鼠体内的比较
PLoS One. 2014 Dec 29;9(12):e115713. doi: 10.1371/journal.pone.0115713. eCollection 2014.
9
Sterilizing immunity elicited by Neisseria meningitidis carriage shows broader protection than predicted by serum antibody cross-reactivity in CEACAM1-humanized mice.在CEACAM1人源化小鼠中,脑膜炎奈瑟菌携带引发的杀菌免疫显示出比血清抗体交叉反应预测的更广泛的保护作用。
Infect Immun. 2015 Jan;83(1):354-63. doi: 10.1128/IAI.02495-14. Epub 2014 Nov 3.
10
Contrasting within- and between-host immune selection shapes Neisseria Opa repertoires.宿主内和宿主间免疫选择的差异塑造了淋病奈瑟菌Opa蛋白谱。
Sci Rep. 2014 Oct 9;4:6554. doi: 10.1038/srep06554.

本文引用的文献

1
Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.多中心、开放性、随机、对照二期临床试验,研究在婴儿期接种含和不含外膜囊泡的新型重组 B 群脑膜炎球菌疫苗的效果。
Clin Infect Dis. 2010 Nov 15;51(10):1127-37. doi: 10.1086/656741. Epub 2010 Oct 18.
2
Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.两种研究用 B 群脑膜炎球菌疫苗在生命第一年的免疫原性:一项随机对照试验。
Pediatr Infect Dis J. 2010 Nov;29(11):e71-9. doi: 10.1097/INF.0b013e3181f59f6d.
3
Opa+ and Opa- isolates of Neisseria meningitidis and Neisseria gonorrhoeae induce sustained proliferative responses in human CD4+ T cells.脑膜炎奈瑟菌和淋病奈瑟菌的Opa+和Opa-分离株可诱导人CD4+ T细胞产生持续的增殖反应。
Infect Immun. 2009 Nov;77(11):5170-80. doi: 10.1128/IAI.00355-09. Epub 2009 Aug 31.
4
Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.使用蛋白质-多糖结合疫苗维持对侵袭性细菌的防护。
Nat Rev Immunol. 2009 Mar;9(3):213-20. doi: 10.1038/nri2494.
5
Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera.补体因子H(fH)与脑膜炎奈瑟菌的结合对人fH具有特异性,并抑制大鼠和兔血清介导的补体激活。
Infect Immun. 2009 Feb;77(2):764-9. doi: 10.1128/IAI.01191-08. Epub 2008 Dec 1.
6
Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor h-binding protein.针对脑膜炎球菌疫苗候选因子H结合蛋白的单克隆抗体的精细抗原特异性和协同杀菌活性
Infect Immun. 2008 Sep;76(9):4232-40. doi: 10.1128/IAI.00367-08. Epub 2008 Jun 30.
7
Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen.针对H因子结合蛋白(一种分布稀疏的脑膜炎球菌疫苗抗原)的抗体的补体依赖性协同杀菌活性。
J Infect Dis. 2008 Apr 1;197(7):1053-61. doi: 10.1086/528994.
8
Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity.脑膜炎球菌C群结合疫苗对带菌状态和群体免疫的影响。
J Infect Dis. 2008 Mar 1;197(5):737-43. doi: 10.1086/527401.
9
Haplotypic diversity in human CEACAM genes: effects on susceptibility to meningococcal disease.人类癌胚抗原相关细胞黏附分子(CEACAM)基因的单倍型多样性:对脑膜炎球菌病易感性的影响。
Genes Immun. 2008 Jan;9(1):30-7. doi: 10.1038/sj.gene.6364442. Epub 2007 Oct 25.
10
Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.A、C、Y及W-135群脑膜炎球菌多糖蛋白结合疫苗
Arch Dis Child. 2007 Oct;92(10):909-15. doi: 10.1136/adc.2006.111500.

重组 Opa 蛋白作为针对高侵袭性脑膜炎奈瑟菌疫苗候选物的潜力。

Potential of recombinant opa proteins as vaccine candidates against hyperinvasive meningococci.

机构信息

Department of Paediatrics, University of Oxford, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Headington, Oxford OX3 7LJ, United Kingdom.

出版信息

Infect Immun. 2011 Jul;79(7):2810-8. doi: 10.1128/IAI.01338-10. Epub 2011 Apr 4.

DOI:10.1128/IAI.01338-10
PMID:21464082
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3191958/
Abstract

Neisseria meningitidis causes half a million cases of septicemia and meningitis globally each year. The opacity (Opa) integral outer membrane proteins from N. meningitidis are polymorphic and highly immunogenic. Particular combinations of Opa proteins are associated with the hyperinvasive meningococcal lineages that have caused the majority of serogroup B and C meningococcal disease in industrialized countries over the last 60 years. For the first time, this genetic structuring of a diverse outer membrane protein family has been used to select a novel combination of representative antigens for immunogenicity testing. Fourteen recombinant Opa variants were produced and used in murine immunizations inducing an increase in specific antimeningococcal total IgG levels. All 14 Opa proteins elicited bactericidal antibodies against at least one hyperinvasive meningococcal isolate, and most isolates from each hyperinvasive lineage were killed by at least one Opa antiserum at a titer of 1:16 or greater. Cross-reactive bactericidal antibody responses were observed among clonal complexes. A theoretical coverage of 90% can be achieved by using a particular combination of 6 Opa proteins against an isolate collection of 227 recent United Kingdom disease cases. This study indicates the potential of Opa proteins to provide broad coverage against multiple meningococcal hyperinvasive lineages.

摘要

脑膜炎奈瑟菌每年在全球范围内导致 50 万例败血症和脑膜炎。脑膜炎奈瑟菌的不透明(Opa)整合外膜蛋白具有多态性和高度免疫原性。特定的 Opa 蛋白组合与高侵袭性脑膜炎奈瑟菌谱系相关,这些谱系在过去 60 年中导致了大多数 B 群和 C 群脑膜炎奈瑟菌病在工业化国家的发生。这是首次将这种多样化的外膜蛋白家族的遗传结构用于选择具有代表性的新型抗原组合进行免疫原性测试。制备了 14 种重组 Opa 变体,并用于小鼠免疫,诱导针对特定抗脑膜炎奈瑟菌总 IgG 水平的增加。所有 14 种 Opa 蛋白均能诱导针对至少一种高侵袭性脑膜炎奈瑟菌分离株的杀菌抗体,并且每种高侵袭性谱系的大多数分离株都至少被一种 Opa 抗血清以 1:16 或更高的效价杀死。在克隆复合物中观察到交叉反应性杀菌抗体反应。使用针对 227 例最近的英国疾病分离株的特定组合的 6 种 Opa 蛋白,可实现 90%的理论覆盖率。这项研究表明 Opa 蛋白有潜力针对多种高侵袭性脑膜炎奈瑟菌谱系提供广泛的覆盖。